- Heterogeneity: Distinction between AT2 and basal cell types. Fibroblast and NE key cell types that distinguish two tumor subtypes from their adjacent tissues.- Key Driver Genes: EGFR, KRAS, BRAF, ERBB2, MET.Potential Therapeutic Targets: Specific subclones of AT2 and basal cells.- Prognosis: Better PFS and ORR with targeted therapies. This evidence concerns the gene KRAS and neoplasm.